Impact Biomedical Inc. financial data

Symbol
IBO on NYSE
Location
1400 Broadfield Blvd., Suite 130, Houston, TX
State of incorporation
NV
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 9.73 %
Return On Equity -15.7 %
Return On Assets -10.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.5M shares -99.7%
Common Stock, Shares, Outstanding 11.5M shares -83.7%
Common Stock, Value, Issued 11K USD -84.3%
Weighted Average Number of Shares Outstanding, Basic 11.5M shares -83.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 82K USD -77%
Selling and Marketing Expense 461K USD +2612%
Costs and Expenses 1.08M USD +21.3%
Operating Income (Loss) -3.66M USD -4.55%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.1M USD
Net Income (Loss) Attributable to Parent -4.56M USD -17.6%
Earnings Per Share, Basic 0.16 USD/shares
Earnings Per Share, Diluted -0.15 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2K USD -33.3%
Accounts Receivable, after Allowance for Credit Loss, Current 128K USD
Assets, Current 3.18M USD +534%
Property, Plant and Equipment, Net 282K USD -2.42%
Goodwill 25.1M USD -45.9%
Assets 46.7M USD +3.58%
Accounts Payable, Current 1M USD +110%
Accrued Liabilities, Current 102K USD +1600%
Liabilities, Current 1.14M USD -90.7%
Deferred Income Tax Liabilities, Net 3.24M USD 0%
Liabilities 12.3M USD -20.4%
Retained Earnings (Accumulated Deficit) -10.6M USD +9.49%
Stockholders' Equity Attributable to Parent 31.3M USD +18.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 34.4M USD +16.1%
Liabilities and Equity 46.7M USD +3.58%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -712K USD +29.8%
Net Cash Provided by (Used in) Financing Activities 713K USD -29.9%
Common Stock, Shares Authorized 4B shares 0%
Common Stock, Shares, Issued 11.5M shares -83.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1K USD
Deferred Tax Assets, Gross 3.55M USD +27.4%
Depreciation 2K USD 0%
Property, Plant and Equipment, Gross 293K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 2.09M USD +29.5%
Preferred Stock, Shares Issued 60.5M shares
Preferred Stock, Shares Authorized 100M shares
Additional Paid in Capital 41.8M USD
Preferred Stock, Shares Outstanding 60.5M shares
Depreciation, Depletion and Amortization 280K USD 0%
Interest Expense 921K USD +199%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares